Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.
Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.
复制标题
DOI:
10.1038/s41598-018-19871-4
复制
发表时间:
2018-02-01
影响因子:
4.6
通讯作者:
Butler LM
中科院分区:
文献类型:
--
作者:
Armstrong HK;Gillis JL;Johnson IRD;Nassar ZD;Moldovan M;Levrier C;Sadowski MC;Chin MY;Tomlinson Guns ES;Tarulli G;Lynn DJ;Brooks DA;Selth LA;Centenera MM;Butler LM
The molecular chaperone Hsp90 is overexpressed in prostate cancer (PCa) and is responsible for the folding, stabilization and maturation of multiple oncoproteins, which are implicated in PCa progression. Compared to first-in-class Hsp90 inhibitors such as 17-allylamino-demethoxygeldanamycin (17-AAG) that were clinically ineffective, second generation inhibitor AUY922 has greater solubility and efficacy. Here, transcriptomic and proteomic analyses of patient-derived PCa explants identified cytoskeletal organization as highly enriched with AUY922 treatment. Validation in PCa cell lines revealed that AUY922 caused marked alterations to cell morphology, and suppressed cell motility and invasion compared to vehicle or 17-AAG, concomitant with dysregulation of key extracellular matrix proteins such as fibronectin (FN1). Interestingly, while the expression of FN1 was increased by AUY922, FN1 secretion was significantly decreased. This resulted in cytosolic accumulation of FN1 protein within late endosomes, suggesting that AUY922 disrupts vesicular secretory trafficking pathways. Depletion of FN1 by siRNA knockdown markedly reduced the invasive capacity of PCa cells, phenocopying AUY922. These results highlight a novel mechanism of action for AUY922 beyond its established effects on cellular mitosis and survival and, furthermore, identifies extracellular matrix cargo delivery as a potential therapeutic target for the treatment of aggressive PCa.
登录
查看更多内容
影响因子:
--
作者:
Hosseini-Beheshti E;Choi W;Weiswald LB;Kharmate G;Ghaffari M;Roshan-Moniri M;Hassona MD;Chan L;Chin MY;Tai IT;Rennie PS;Fazli L;Tomlinson Guns ES
通讯作者:
Tomlinson Guns ES
DOI:
10.1186/bcr1996
发表时间:
2008
期刊:
Breast cancer research : BCR
影响因子:
--
作者:
Jensen MR;Schoepfer J;Radimerski T;Massey A;Guy CT;Brueggen J;Quadt C;Buckler A;Cozens R;Drysdale MJ;Garcia-Echeverria C;Chène P
通讯作者:
Chène P
影响因子:
12.3
作者:
Carpenter AE;Jones TR;Lamprecht MR;Clarke C;Kang IH;Friman O;Guertin DA;Chang JH;Lindquist RA;Moffat J;Golland P;Sabatini DM
通讯作者:
Sabatini DM
影响因子:
4.3
作者:
Cox TR;Erler JT
通讯作者:
Erler JT
影响因子:
2.7
作者:
Beswick, RW;Ambrose, HE;Wagner, SD
通讯作者:
Wagner, SD